IL115738A - Competitive progesterone antagonists for regulating female fertility as required - Google Patents

Competitive progesterone antagonists for regulating female fertility as required

Info

Publication number
IL115738A
IL115738A IL11573895A IL11573895A IL115738A IL 115738 A IL115738 A IL 115738A IL 11573895 A IL11573895 A IL 11573895A IL 11573895 A IL11573895 A IL 11573895A IL 115738 A IL115738 A IL 115738A
Authority
IL
Israel
Prior art keywords
phenyl
hydroxy
progesterone antagonist
competitive progesterone
administration
Prior art date
Application number
IL11573895A
Other languages
English (en)
Other versions
IL115738A0 (en
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL115738A0 publication Critical patent/IL115738A0/xx
Publication of IL115738A publication Critical patent/IL115738A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL11573895A 1994-10-24 1995-10-24 Competitive progesterone antagonists for regulating female fertility as required IL115738A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4438820 1994-10-24

Publications (2)

Publication Number Publication Date
IL115738A0 IL115738A0 (en) 1996-01-19
IL115738A true IL115738A (en) 2002-05-23

Family

ID=6532105

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11573895A IL115738A (en) 1994-10-24 1995-10-24 Competitive progesterone antagonists for regulating female fertility as required

Country Status (25)

Country Link
US (1) US6143754A (cs)
EP (1) EP0787002B1 (cs)
JP (1) JPH10507461A (cs)
KR (1) KR970706827A (cs)
CN (1) CN1211087C (cs)
AT (1) ATE347894T1 (cs)
AU (1) AU707235B2 (cs)
BG (1) BG62877B1 (cs)
BR (1) BR9509478A (cs)
CA (1) CA2203541A1 (cs)
CZ (1) CZ290690B6 (cs)
DE (1) DE59511071D1 (cs)
DK (1) DK0787002T3 (cs)
ES (1) ES2279515T3 (cs)
FI (1) FI971742L (cs)
HU (1) HU226566B1 (cs)
IL (1) IL115738A (cs)
NO (1) NO314437B1 (cs)
NZ (1) NZ295365A (cs)
PL (1) PL319869A1 (cs)
PT (1) PT787002E (cs)
RO (1) RO120606B1 (cs)
SK (1) SK283662B6 (cs)
WO (1) WO1996012494A1 (cs)
ZA (1) ZA959008B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
CN1454088A (zh) * 1999-08-31 2003-11-05 耶拿制药两合公司 中孕酮(孕酮受体调节剂)作为激素替代疗法(hrt)用组合物的一个组分的应用
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
SI20853A (sl) * 1999-08-31 2002-10-31 Jenapharm Gmbh & Co. Kg Mezoprogestini (modulatorji receptorja progesterona) kot sestavina ženskih kontraceptivov
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
EP2234491A4 (en) * 2007-12-20 2010-12-22 Teva Womens Health Inc DOSAGE SCHEMES AND PHARMACEUTICAL COMPOSITIONS AND PACKAGING FOR EMERGENCY CONTRACEPTION
ES2602134T3 (es) 2009-04-14 2017-02-17 Laboratoire Hra Pharma Procedimiento para anticoncepción bajo demanda
CA2758764C (en) * 2009-04-14 2017-04-11 Elizabeth Gray Raymond Method for on-demand contraception using levonorgestrel or norgestrel
BR112015029214A2 (pt) 2013-05-23 2017-07-25 Bayer Pharma AG composição farmacêutica, seu uso e regime de aplicação dessa composição farmacêutica para contracepção conforme a necessidade
JP6655075B2 (ja) 2014-11-17 2020-02-26 コンテクスト バイオファーマ インコーポレイテッド オナプリストン持続放出組成物および方法
JP2018528944A (ja) 2015-09-25 2018-10-04 コンテクスト バイオファーマ インコーポレイテッド オナプリストン中間体の製造方法
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein

Also Published As

Publication number Publication date
CN1161649A (zh) 1997-10-08
ZA959008B (en) 1996-09-16
WO1996012494A1 (de) 1996-05-02
BG101427A (en) 1997-11-28
NO971869D0 (no) 1997-04-23
EP0787002B1 (de) 2006-12-13
MX9703018A (es) 1997-10-31
ES2279515T3 (es) 2007-08-16
EP0787002A1 (de) 1997-08-06
AU707235B2 (en) 1999-07-08
FI971742A0 (fi) 1997-04-23
NO314437B1 (no) 2003-03-24
FI971742A7 (fi) 1997-04-23
CZ118097A3 (en) 1997-07-16
NZ295365A (en) 1999-07-29
SK283662B6 (sk) 2003-11-04
IL115738A0 (en) 1996-01-19
CN1211087C (zh) 2005-07-20
DE59511071D1 (de) 2007-01-25
HUT77518A (hu) 1998-05-28
BR9509478A (pt) 1997-09-30
BG62877B1 (bg) 2000-10-31
PL319869A1 (en) 1997-09-01
JPH10507461A (ja) 1998-07-21
DK0787002T3 (da) 2007-04-10
SK51897A3 (en) 1997-09-10
FI971742L (fi) 1997-04-23
CZ290690B6 (cs) 2002-09-11
KR970706827A (ko) 1997-12-01
AU3869695A (en) 1996-05-15
PT787002E (pt) 2007-03-30
CA2203541A1 (en) 1996-05-02
US6143754A (en) 2000-11-07
NO971869L (no) 1997-04-23
ATE347894T1 (de) 2007-01-15
RO120606B1 (ro) 2006-05-30
HU226566B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
US6362237B1 (en) Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US6225297B1 (en) Combination contraceptive
US5719136A (en) Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women
EP0792152B1 (en) Methods of contraception
US6043234A (en) Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen
US6143754A (en) Competitive progesterone antagonist for demand-oriented female birth control
Bygdeman et al. Contraceptive use of antiprogestin
US6642219B1 (en) Progestogen-antiprogestogen regimens
BG106441A (bg) Мезопрогестини (модулатори на прогестероновия рецептор) като компоненти на женски контрацептиви
JPH08510992A (ja) 受精の阻止及び防止方法
MXPA97003018A (es) Antagonistas de progesterona competentes para regular la fertilidad femenina segun se requiera

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees